Abstract:Objective To investigate the clinical effect of Cetuximab Solution for infusion combined with FOLFOX4 chemotherapy in treatment of metastatic colorectal cancer.Methods Patients (75 cases) with metastatic colorectal cancer in 85 Hospital of People's Liberation Army from June 2014 to December 2015 were randomly divided into the control group (37 cases) and the treatment group (38 cases). Patients in the control group were treated with FOLFOX4 chemotherapy and iv administered with Oxaliplatin for injection in the first day treatment, 85 mg/m2 added into normal saline 250 mL. And they were also iv administered with Fluorouracil Injection in the first and second day treatment, 300 mg/m2 added into normal saline 250 mL. In the same time, patients in the control group were iv administered with Calcium Folinate Injection in the first and second day treatment, 400 mg/m2 added into normal saline 250 mL. Patients in the treatment group were iv administered with Cetuximab Solution for infusion on the basis of the control group, 500 mg/m2, intravenous infusion of 2 h at the first time, followed by intravenous infusion of 1 h, once weekly. Patients in two groups were treated for 4 courses, 2 weeks as one course. After treatment, the clinical efficacies were evaluated, and tumor marker levels and adverse reactions in two groups were compared.Results After treatment, the clinical efficacies in the control and treatment groups were 40.5% and 52.6%, respectively, the disease control rates in two groups were 70.3% and 89.5%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of CEA and CA199 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). The total incidence of skin rash in the control and treatment groups were 8.11% and 34.2%, respectively, and there was difference between two groups (P < 0.05). But the other adverse reactions had no significant difference between two groups.Conclusion Cetuximab Solution for infusion combined with FOLFOX4 chemotherapy has clinical curative effect in treatment of metastatic colorectal cancer, can decrease tumor marker levels with good safety, which has a certain clinical application value.

Effects of Cetuximab Plus Chemotherapy in First-Line Treatment of Advanced Colorectal Cancer

Cetuximab Plus Mfolfox-6 As First-Line Therapy for Unresectable Liver Metastasis from Colorectal Cancer: an Open, Non-Randomized, Multicenter Phase Ii Clinical Trial

Cetuximab Enhanced the Cytotoxic Activity of Immune Cells During Treatment of Colorectal Cancer

Retrospective Study of Cetuximab in Combination with Chemotherapy for Patients with Colorectal Cancer

Effect of cetuximab combined with FUFOX regimen in treatment of patients with advanced colorectal cancer

[Cetuximab in Combination with Chemotherapy for Patients with Gastrointestinal Cancer].

Clinical Progress of Anti-Epidermal Growth Factor Receptor Antibody,cetuximab, in the Treatment of Colorectal Cancer

Clinical study on cetuximab combined with FOLFOX4 chemotherapy in treatment of metastatic colorectal cancer

Efficacy and Immune Mechanisms of Cetuximab for the Treatment of Metastatic Colorectal Cancer

Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial

The Clinical Observation of Cetuximab in Combination with Chemotherapy in Metastatic Colorectal Cancer Patients

Cetuximab Combined with FOLFOX4 As the First-Line Treatment for Advanced Gastric Cancer: Report of 25 Cases from a Single Institution

Complete Response With Cetuximab-Based Treatment of Metastatic Colorectal Cancers: Two Case Reports and Literature Review

Cetuximab plus Oxaliplatin-Based Chemotherapy for Metastatic Colorectal Cancer: a Systematic Review and Meta-Analysis

A Meta-Analysis of Cetuximab Combined with Chemotherapy in the Treatment of Advanced Colorectal Cancer

Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients with KRAS Wild-Type Unresectable Colorectal Liver-Limited Metastases.

Cetuximab Plus Irinotecan in Treatment of Metastatic Colorectal Cancer

Cetuximab plus other methods in the treatment of patients with head and neck squamous cell carcinomas(HNSCC)

Effect of cetuximab plus FOLFOX4 regimen on clinical outcomes in advanced gastric carcinoma patients receiving evidence-based care

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis.